Citations

Clear

19 citation(s) found for "Johnson, Scott".

Agitation Techniques to Enhance Drainage of Retained Hemothorax
Makey, Ian A. , Das, Nitin A. , Jacob, Samuel , Ahmed, Magdy M. El‐Sayed , Makey, Colleen M. , Johnson, Scott B., Thomas, Mathew , Thomas, Mathew , Thomas, Mathew , Makey, Ian , Makey, Colleen M., Johnson, Scott

Mayo Clinic

Surgical Innovation | December 18, 2020 | Volume: 28 | Issue: 5 | Pages: 544-551

10.1177/1553350620978002 | PMID 33339490 Get It

Background. Retained hemothorax (RH) is a common problem in cardiothoracic and trauma surgery. We aimed to determine the optimum agitation technique to enhance thrombus dissolution and drainage and to apply the technique to a porcine-retained hemothorax. Methods. Three agitation techniques were tested: flush irrigation, ultrasound, and vibration. We used the techniques in a benchtop model with tissue plasminogen activator (tPA) and pig hemothorax with tPA. We used the most promising technique vibration in a pig hemothorax without tPA. Statistics. We used 2-sample t tests for each comparison and Cohen d tests to calculate effect size (ES). Results. In the benchtop model, mean drainages in the agitation group and control group and the ES were flush irrigation, 42%, 28%, and 2.91 ( P = .10); ultrasound, 35%, 27%, and .76 ( P = .30); and vibration, 28%, 19%, and 1.14 ( P = .04). In the pig hemothorax with tPA, mean drainages and the ES of each agitation technique compared with control (58%) were flush irrigation, 80% and 1.14 ( P = .37); ultrasound, 80% and 2.11 ( P = .17); and vibration, 95% and 3.98 ( P = .06). In the pig hemothorax model without tPA, mean drainages of the vibration technique and control group were 50% and 43% (ES = .29; P = .65). Discussion. In vitro studies suggested flush irrigation had the greatest effect, whereas only vibration was significantly different vs the respective controls. In vivo with tPA, vibration showed promising but not statistically significant results. Results of in vivo experiments without tPA were negative. Conclusion. Agitation techniques, in combination with tPA, may enhance drainage of hemothorax.
Comparison of Tissue-Based Molecular Markers in Younger versus Older Patients with Colorectal Neoplasia
Ahlquist, David A. , Allawi, Hatim T. , Kaiser, Michael W., Katerov, Viatcheslav E. , Statz, Sandra , Graham, Rondell P. , Burger, Kelli N. , Lidgard, Graham P. , Limburg, Paul J. , Mahoney, Douglas W. , Graham, Rondell P , Foote, Patrick H. , Doering, Karen A , Kisiel, John B , Johnson, Scott C., Doering, Karen A. , Kisiel, John B.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 28, 2020 | Volume: 29 | Issue: 8 | Pages: 1570-1576

10.1158/1055-9965.epi-19-1598 | PMID 32467348 Get It

Abstract Background: Emerging colorectal cancer trends demonstrate increased incidence and mortality in younger populations, prompting consideration of average-risk colorectal cancer screening initiation at age 45 versus 50 years. However, screening test performance characteristics in adults 45–49 years have been minimally described. To inform the biologic rationale for multi-target stool DNA (mt-sDNA) screening in younger patients, we analyzed and compared tissue levels of methylation (BMP3, NDRG4) and mutation (KRAS) markers included in the FDA-approved, mt-sDNA assay (Cologuard; Exact Sciences Corporation). Methods: Within 40–44, 45–49, and 50–64 year age groups, archived colorectal tissue specimens were identified for 211 sporadic colorectal cancer cases, 123 advanced precancerous lesions (APLs; adenomas >1 cm, high-grade dysplasia, ≥25% villous morphology, or sessile serrated polyp; 45–49 and 50–64 age groups only), and 204 histologically normal controls. Following DNA extraction, KRAS, BMP3, and NDRG4 were quantified using QuARTS assays, relative to ACTB (reference gene). Results: None of the molecular marker concentrations were significantly associated with age (P > 0.05 for all comparisons), with the exception of NDRG4 concentration in APL samples (higher in older vs. younger cases; P = 0.008). However, NDRG4 levels were also statistically higher in APL case versus normal control samples in both the 45–49 (P < 0.0001) and 50–64 (P < 0.0001) year age groups. Conclusions: Overall, these findings support the potential for earlier onset of average-risk colorectal cancer screening with the mt-sDNA assay. Impact: These novel data address an identified knowledge gap and strengthen the biologic basis for earlier-onset, average-risk screening with the mt-sDNA assay.
Algorithm for blood-based panel of methylated DNA and protein markers to detect early-stage hepatocellular carcinoma with high specificity.
Chalasani, Naga , Bhattacharya, Abhik , Book, Adam, Neis, Brenda M., Xiong, Kong, Ramasubramanian, Tiruvidaimarudur S., Lidgard, Graham P. , Reddy, K.R., Olson, Marilyn C. , Bruinsma, Janelle J., Book, Adam J. , Johnson, Scott, Roberts, Lewis R. , Kisiel, John B. , Singal, Amit G.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 4577-4577

10.1200/jco.2020.38.15_suppl.4577 Get It

4577 Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Though biannual ultrasound surveillance with or without alpha-fetoprotein (AFP) testing is recommended for at-risk patients, its sensitivity for early-stage HCC detection is suboptimal. We therefore evaluated performance of a biomarker panel incorporating methylated DNA markers (MDMs) and proteins for early HCC detection in at-risk patients with chronic liver disease. Methods: In an international, multicenter, case-control study, blood specimens were collected from patients with HCC per AASLD criteria and controls matched for age and liver disease etiology. All patients had underlying cirrhosis or chronic HBV infection. Whole blood was collected in cell-free DNA stabilizing and serum-separation tubes and shipped to a central laboratory for processing. The levels of 5 MDMs, AFP, and AFP-L3 were assessed along with age and sex. We used 537 samples in a 5-fold validation for developing a LASSO regression algorithm to classify samples as HCC positive or negative. Model robustness was tested by perturbing the data in silico and analyzing results with the predictive algorithm. Algorithm performance was compared to AFP alone and the GALAD score (Gender, Age, AFP-L3, AFP, and DCP). Results: The study included 136 HCC cases (81 early-stage—BCLC stage 0/A) and 401 controls. With specificity set at 89%, we developed a model using sex, AFP, and 3 MDMs (HOXA1, TSPYL5, B3GALT6) with higher sensitivity (70%) for early-stage HCC compared to GALAD (54%) or AFP (31% at 20 ng/mL or 52% at ≥7.7 ng/mL) (Table). The AUC for the HCC marker panel was 0.91 (95% CI 0.89 – 0.94) compared to GALAD (0.88; 95% CI 0.85 – 0.91) or AFP (0.84; 95% CI 0.81 – 0.87). The panel performed similarly in viral (AUC = 0.94) and non-viral (AUC = 0.89) etiologies. Conclusions: The robust algorithm based on novel blood-based biomarkers presented here provides higher sensitivity for early-stage HCC compared to other available blood-based biomarkers and, therefore, could significantly impact HCC clinical management and patient outcomes. Further clinical studies to validate the algorithm are ongoing. Clinical trial information: NCT03628651 . [Table: see text]
325 Novel Multi-Target Stool DNA Marker Panel Yields Highly Accurate Detection of Colorectal Cancer and Premalignant Neoplasia
Domanico, Michael J. , Bourne, Bridget L, Allawi, Hatim T. , Matter, Michael B. , Ahlquist, David A. , Lidgard, Graham P. , Kisiel, John B. , Gagrat, Zubin D. , Taylor, William R. , Leduc, Christine M. , Mahoney, Douglas W. , Limburg, Paul J. , Johnson, Scott

Mayo Clinic

American Journal of Gastroenterology | October 8, 2019 | Volume: 114 | Issue: 1 | Pages: S191-S191

10.14309/01.ajg.0000590832.76462.30 Get It

INTRODUCTION: Despite the demonstrated effectiveness of average-risk screening, colorectal cancer (CRC) remains the 2 nd leading cause of cancer death in the US. For optimal prevention, CRC screening tools should be highly accurate, user-friendly, and broadly accessible. Patient and provider adoption of the FDA-approved, guideline-endorsed multi-target stool DNA (mt-sDNA) test has grown exponentially since its launch in 2014. Toward ongoing improvement in CRC screening effectiveness, we conducted a blinded case-control study to assess the detection accuracy of a mt-sDNA panel of novel, highly discriminant methylated DNA markers (MDMs). METHODS: We selected 12 candidate MDMs from prior whole methylome discovery and validation in tissue. Stool was obtained as part of previous large, multicenter studies and collected prior to or 7 days post-colonoscopy (prior to any clinically-indicated treatment). CRC, advanced adenoma (AA; size ≥1 cm, high-grade dysplasia, or ≥25% villous morphology), non-AA, or control (no neoplasia) status was defined by colonoscopy and histopathology. Samples were blinded to operators and randomized by characterization to balance the test sets prior to assessment. MDMs were quantified by target-specific DNA capture and Long-probe Quantitative Amplified Signal assay on bisulfite-converted DNA; fecal hemoglobin was quantified by immunoassay. Bootstrapping methods were used to select a panel of 3 MDMs, which was then 10-fold cross-validated; hemoglobin was also included, as was a colon epithelium-specific MDM to normalize stool MDM levels. RESULTS: Participant samples included 117 CRC, 120 AA, 161 non-AA, and 327 controls. Median age was 67 (IQR 61, 75) years; 51% were men. The AUC with best-fit was 0.97 for CRC and 0.84 for AA, and these high AUCs held up tightly on cross-validation (Figure 1). At 92% (95% CI 88-94%) specificity, sensitivity of the panel was 92% (95% CI 86-96%) for CRC. Neither CRC stage (Figure 2) nor CRC site significantly affected performance. At the same 92% specificity, sensitivity was 65% (95% CI 56-73%) for AAs overall, 67% (38-88%) for sessile serrated polyps ≥1 cm, and 71% (57-82%) for adenomas with villous features (Figure 3). CONCLUSION: These data support highly accurate performance of a novel panel of mt-sDNA markers for detecting both CRC (including early stage lesions) and AAs at greatest risk of progression. Prospective comparative studies are warranted to further establish the clinical potential of this novel screening tool.
273 Multi-Target DNA Aberrations in Sporadic Colorectal Cancer Tissues Do Not Differ Between Younger and Older Patients
Ahlquist, David A. , Allawi, Hatim T. , Kaiser, Michael W., Statz, Sandra , Burger, Kelli N. , Lidgard, Graham P. , Limburg, Paul J. , Mahoney, Douglas W. , Johnson, Scott, Graham, Rondell P. , Foote, Patrick H. , Doering, Karen A. , Kisiel, John B.

Mayo Clinic

American Journal of Gastroenterology | October 8, 2019 | Volume: 114 | Issue: 1 | Pages: S160-S160

10.14309/01.ajg.0000590624.23097.83 Get It

INTRODUCTION: Colorectal cancer (CRC) screening is broadly endorsed for individuals 50–75 years of age. Given recent increases in CRC incidence and mortality for patients <50 years old, the American Cancer Society now recommends initiation of average-risk CRC screening at age 45 (Wolf AMD CA Cancer J Clin 2018). The performance of recommended tests, including the multi-target stool DNA (mt-sDNA; marketed as Cologuard™) test, has been minimally described in populations under 50 years old. To address this knowledge gap, we conducted a retrospective study of DNA markers (KRAS, BMP3, NDRG4) included in the mt-sDNA assay to quantify and compare tissue marker levels in sporadic CRC cases and normal colon controls from patients in 45–49 and 50–64 year-old age groups. Our primary hypothesis was that mt-sDNA marker levels would be statistically similar between cases in both age groups. METHODS: Patient samples were identified from a pathology tissue archive at Mayo Clinic, excluding those with inflammatory bowel disease or familial cancer syndromes. Formalin-fixed, paraffin-embedded tissues were reviewed by a GI pathologist for 45–49 year-old (n = 90) and 50–64 year-old (n = 96) CRC cases; normal colon samples (45–49, n = 76; 50–64, n = 92) were also included for comparison. DNA extracted from core punches was blinded and processed in a randomized order. Quantitative Allele specific Realtime Target and Signal amplification (QuARTS) assays were used to quantify KRAS mutations, and BMP3 and NDRG4 methylation. Marker level in each sample was reported as the QuARTS product of mutant KRAS , methylated BMP3 or NDRG4 relative to the ACTB product in each sample, reported as a percentage. At least 60 patients per group provided sufficient power to demonstrate differences in marker levels of ±25% between case groups and between control groups using the Wilcoxon Rank Sum test. RESULTS: CRC cases in the 45–49 vs 50–64 year-old groups did not differ significantly with respect to sex ( P = 0.77) or race/ethnicity ( P = 0.06); left-sided CRC was more common in the 45–49 vs 50–64 year-old group (87% vs. 72%; P = 0.02). None of the marker levels were statistically different between cases of the younger vs older groups or between controls of these groups (Figure 1). CONCLUSION: These data support the expectation of no age-related differences in CRC detection by mt-sDNA, as the relevant molecular markers, when they occur, are present at similar levels across age groups 45–49 and 50–64 years.
How to select patients for antireflux surgery? The ICARUS guidelines (international consensus regarding preoperative examinations and clinical characteristics assessment to select adult patients for antireflux surgery)
Pauwels, Ans, Andrews, Christopher N. , Attwood, Stephen , Berrisford, Richard, Bisschops, Raf , Boeckxstaens, Guy E. , Bor, Serhat , Bredenoord, Albert J. , Cicala, Michele , Corsetti, Maura , Fornari, Fernando , Gyawali, C. Prakash , Hatlebakk, Jan, Johnson, Scott, Lerut, Toni, Lundell, Lars, Mattioli, Sandro , Omari, Taher , Pandolfino, John E. , Penagini, Roberto , Rice, Thomas W., Roelandt, Philip , Rommel, Nathalie , Savarino, Vincenzo , Vanuytsel, Tim , Vela, Marcelo F. , Watson, David I. , Tack, Jan , Lerut, Antoon , Tack, Jan , Gyawali, C P , Corsetti, M , Penagini, Roberto , Bisschops, Raf , Bor, Serhat , Omari, Taher , Boeckxstaens, Guy , Andrews, Christopher N , Boecxstaens, Veerle , Miwa, Hiroto , Nafteux, Philippe Robert , Sifrim, Daniel , Suzuki, Hidekazu , Tutuian, Radu I. , Zerbib, Frank

Mayo Clinic

Gut | August 2, 2019 | Volume: 68 | Issue: 11 | Pages: 1928-1941

10.1136/gutjnl-2019-318260 | PMID 31375601 Get It

Objective Antireflux surgery can be proposed in patients with GORD, especially when proton pump inhibitor (PPI) use leads to incomplete symptom improvement. However, to date, international consensus guidelines on the clinical criteria and additional technical examinations used in patient selection for antireflux surgery are lacking. We aimed at generating key recommendations in the selection of patients for antireflux surgery. Design We included 35 international experts (gastroenterologists, surgeons and physiologists) in a Delphi process and developed 37 statements that were revised by the Consensus Group, to start the Delphi process. Three voting rounds followed where each statement was presented with the evidence summary. The panel indicated the degree of agreement for the statement. When 80% of the Consensus Group agreed (A+/A) with a statement, this was defined as consensus. All votes were mutually anonymous. Results Patients with heartburn with a satisfactory response to PPIs, patients with a hiatal hernia (HH), patients with oesophagitis Los Angeles (LA) grade B or higher and patients with Barrett’s oesophagus are good candidates for antireflux surgery. An endoscopy prior to antireflux surgery is mandatory and a barium swallow should be performed in patients with suspicion of a HH or short oesophagus. Oesophageal manometry is mandatory to rule out major motility disorders. Finally, oesophageal pH (±impedance) monitoring of PPI is mandatory to select patients for antireflux surgery, if endoscopy is negative for unequivocal reflux oesophagitis. Conclusion With the ICARUS guidelines, we generated key recommendations for selection of patients for antireflux surgery.
Lung transplant patients with coronary artery disease rarely die of cardiac causes
Makey, Ian A. , Sui, Jin W., Huynh, Charles, Das, Nitin A. , Thomas, Mathew , Johnson, Scott, Thomas, Mathew , Thomas, Mathew , Huynh, Charles, Thomas, Mathew

Mayo Clinic

Clinical Transplantation | July 19, 2018 | Volume: 32 | Issue: 9 | Pages: No page available

10.1111/ctr.13354 | PMID 30022532 Get It

AbstractBackgroundA relative contraindication for lung transplant (LT) is coronary disease burden sufficient to cause risk of myocardial infarction after LT. We analyzed cause of death and outcomes of our LT patients with coronary artery disease (CAD).MethodsInpatient records from March 1, 2004, to January 31, 2015, were retrospectively examined and data of 306 LTs extracted. Twenty‐five patients without coronary angiography (CA) and 7 with redo LTs were excluded. The other 274 patients were divided into 2 groups: CAD (n = 116) and no CAD (n = 158). Patients with prior revascularization or coronary stenosis >10% were placed into the CAD group.ResultsThe CAD group was older and had more male patients, greater history of smoking and hypertension, and greater proportion of patients with interstitial lung disease than the no‐CAD group. CAD patients were more likely to receive a single‐lung transplant. Death of cardiac causes occurred for 2 patients (1.7%) in the CAD group and for 1 patient (0.6%) in the no‐CAD group (P = 0.39).ConclusionsThis analysis shows that compared with patients who have no CAD, patients with CAD have different demographic characteristics and receive more single‐lung transplants. Incidence of death of cardiac causes is rare.
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Lesokhin, Alexander M. , Ansell, Stephen M. , Armand, Philippe , Halwani, Ahmad , Gutierrez, Martin , Millenson, Michael, Cohen, Adam D. , Lebovic, Daniel, Dhodapkar, Madhav V. , Avigan, David , Chapuy, Bjoern , Ligon, Azra H. , Freeman, Gordon J. , Cattry, Deepika, Zhu, Lili, Grosso, Joseph F., Garelik, M. Brigid, Borrello, Ivan , Timmerman, John M. , Scott, Emma C. , Millenson, Michael M, Schuster, Stephen J. , Dhodapkar, Madhav, Rodig, Scott J, Bradley Garelik, M Brigid, Shipp, Margaret A, Timmerman, John, Scott, Emma , Rodig, Scott J , Zhu, Lili, Shipp, Margaret Ann , Lesokhin, Alexander M , Cohen, Adam D

Mayo Clinic

Journal of Clinical Oncology | June 6, 2016 | Volume: 34 | Issue: 23 | Pages: 2698-2704

10.1200/jco.2015.65.9789 | PMID 27269947 Get It

Purpose Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint pathway to avoid immune surveillance by modulating T-lymphocyte activity. In part, this may occur through overexpression of PD-1 and PD-1 pathway ligands (PD-L1 and PD-L2) in the tumor microenvironment. PD-1 blockade has produced significant antitumor activity in solid tumors, and similar evidence has emerged in hematologic malignancies. Methods In this phase I, open-label, dose-escalation, cohort-expansion study, patients with relapsed or refractory B-cell lymphoma, T-cell lymphoma, and multiple myeloma received the anti–PD-1 monoclonal antibody nivolumab at doses of 1 or 3 mg/kg every 2 weeks. This study aimed to evaluate the safety and efficacy of nivolumab and to assess PD-L1/PD-L2 locus integrity and protein expression. Results Eighty-one patients were treated (follicular lymphoma, n = 10; diffuse large B-cell lymphoma, n = 11; other B-cell lymphomas, n = 10; mycosis fungoides, n = 13; peripheral T-cell lymphoma, n = 5; other T-cell lymphomas, n = 5; multiple myeloma, n = 27). Patients had received a median of three (range, one to 12) prior systemic treatments. Drug-related adverse events occurred in 51 (63%) patients, and most were grade 1 or 2. Objective response rates were 40%, 36%, 15%, and 40% among patients with follicular lymphoma, diffuse large B-cell lymphoma, mycosis fungoides, and peripheral T-cell lymphoma, respectively. Median time of follow-up observation was 66.6 weeks (range, 1.6 to 132.0+ weeks). Durations of response in individual patients ranged from 6.0 to 81.6+ weeks. Conclusion Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas. Additional studies of nivolumab in these diseases are ongoing.
Detection and Quantification of Hepatitis C Virus (HCV) by MultiCode-RTx Real-Time PCR Targeting the HCV 3′ Untranslated Region
Mulligan, Elizabeth K., Germer, Jeffery J., Arens, Max Q., D'Amore, Krista L., Bisceglie, Adrian M. Di , Ledeboer, Nathan A., Moser, Michael J., Newman, Andrew, O'Guin, Andy K., Olivo, Paul D. , Podzorski, Diane, Vaughan, Kimberly A., Yao, Joseph D. , Elagin, Slava, Johnson, Scott C.

Mayo Clinic

Journal of Clinical Microbiology | June 18, 2009 | Volume: 47 | Issue: 8 | Pages: 2635-2638

10.1128/jcm.02170-08 | PMID 19535519 Get It

ABSTRACT A prototype, real-time reverse-transcription PCR assay, based on MultiCode-RTx technology, quantifying hepatitis C virus (HCV) RNA by targeting the HCV 3′ untranslated region demonstrated linearity over 7 logs, with a good correlation between the quantitative results of this assay and the results of two commercially available comparator assays for 466 clinical specimens comprising all six HCV genotypes.